JP2018534348A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534348A5
JP2018534348A5 JP2018534496A JP2018534496A JP2018534348A5 JP 2018534348 A5 JP2018534348 A5 JP 2018534348A5 JP 2018534496 A JP2018534496 A JP 2018534496A JP 2018534496 A JP2018534496 A JP 2018534496A JP 2018534348 A5 JP2018534348 A5 JP 2018534348A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
item
composition according
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018534496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534348A (ja
JP6849686B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/052922 external-priority patent/WO2017053455A1/en
Publication of JP2018534348A publication Critical patent/JP2018534348A/ja
Publication of JP2018534348A5 publication Critical patent/JP2018534348A5/ja
Application granted granted Critical
Publication of JP6849686B2 publication Critical patent/JP6849686B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018534496A 2015-09-21 2016-09-21 重水素化されたｃｆｔｒ増強剤の投与 Active JP6849686B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562221531P 2015-09-21 2015-09-21
US62/221,531 2015-09-21
US201562238511P 2015-10-07 2015-10-07
US62/238,511 2015-10-07
US201662348855P 2016-06-10 2016-06-10
US62/348,855 2016-06-10
PCT/US2016/052922 WO2017053455A1 (en) 2015-09-21 2016-09-21 Administration of deuterated cftr potentiators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021034591A Division JP7196217B2 (ja) 2015-09-21 2021-03-04 重水素化されたｃｆｔｒ増強剤の投与

Publications (3)

Publication Number Publication Date
JP2018534348A JP2018534348A (ja) 2018-11-22
JP2018534348A5 true JP2018534348A5 (OSRAM) 2019-11-07
JP6849686B2 JP6849686B2 (ja) 2021-03-24

Family

ID=58387264

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018534496A Active JP6849686B2 (ja) 2015-09-21 2016-09-21 重水素化されたｃｆｔｒ増強剤の投与
JP2021034591A Active JP7196217B2 (ja) 2015-09-21 2021-03-04 重水素化されたｃｆｔｒ増強剤の投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021034591A Active JP7196217B2 (ja) 2015-09-21 2021-03-04 重水素化されたｃｆｔｒ増強剤の投与

Country Status (16)

Country Link
US (2) US20180353500A1 (OSRAM)
EP (2) EP4292588A3 (OSRAM)
JP (2) JP6849686B2 (OSRAM)
KR (1) KR102828163B1 (OSRAM)
CN (1) CN108367002A (OSRAM)
AU (2) AU2016326441B2 (OSRAM)
BR (1) BR112018005454A2 (OSRAM)
CA (1) CA2998911C (OSRAM)
HK (1) HK1258472A1 (OSRAM)
IL (2) IL257993A (OSRAM)
MA (1) MA42950A (OSRAM)
MX (1) MX388470B (OSRAM)
RU (1) RU2761344C2 (OSRAM)
SG (1) SG10201913588YA (OSRAM)
UA (1) UA124619C2 (OSRAM)
WO (1) WO2017053455A1 (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
HK1249893A1 (zh) 2015-03-31 2018-11-16 Vertex Pharmaceuticals (Europe) Limited 氘代vx-661
UA124619C2 (uk) 2015-09-21 2021-10-20 Вертекс Фармасьютікалз (Юроп) Лімітед Введення дейтерованих підсилювачів cftr
HK1258473A1 (zh) 2015-09-25 2019-11-15 Vertex Pharmaceuticals (Europe) Limited 氘代cftr增效剂
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
US20200171015A1 (en) * 2017-07-17 2020-06-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CA3082444A1 (en) 2017-12-01 2019-06-06 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
AU2019222758B2 (en) 2018-02-15 2022-07-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
PT3880197T (pt) 2018-11-14 2023-05-09 Vertex Pharma Métodos de tratamento para a fibrose quística
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
FR3096890B1 (fr) 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CA3150162A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
CN114585628B (zh) 2019-08-14 2024-03-26 弗特克斯药品有限公司 囊性纤维化跨膜传导调节因子的调节剂
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
FR3109524B1 (fr) 2020-04-22 2022-04-08 H4 Orphan Pharma Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales.
FR3111071B1 (fr) 2020-06-04 2023-01-13 H4 Orphan Pharma Utilisation de ligands multifonctionnels pour traiter les syndromes de détresse respiratoire et le choc cytokinique liés aux infections virales à coronavirus.
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators
US20230373935A1 (en) 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225765A2 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076628A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225762A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225447A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2023004074A (es) 2020-10-07 2023-07-05 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
WO2022076629A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225446A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
IL314449A (en) 2022-02-03 2024-09-01 Vertex Pharma Methods of treatment for cystic fibrosis
WO2023154291A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
IL315715A (en) 2022-04-06 2024-11-01 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulation
EP4525858A1 (en) 2022-05-16 2025-03-26 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2025076235A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2025076240A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cystic fibrosis transmembrane conductance regulator
WO2025166342A1 (en) 2024-02-04 2025-08-07 Vertex Pharmaceuticals Incorporated Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis
US20250248981A1 (en) 2024-02-07 2025-08-07 Vertex Pharmaceuticals Incorporated Compositions for the treatment of cftr-mediated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CN1255185C (zh) 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
MX2007003731A (es) 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
HRP20180328T1 (hr) 2008-08-13 2018-04-20 Vertex Pharmaceuticals Inc. FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
CA2798412A1 (en) * 2010-05-20 2011-11-24 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
HUE047354T2 (hu) * 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
JP6063455B2 (ja) * 2011-05-18 2017-01-18 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたイバカフトルの誘導体
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
MY183582A (en) * 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
CN109364075B (zh) * 2012-11-21 2021-10-29 顶点制药（欧洲）有限公司 氘化cftr增效剂
US20140221424A1 (en) * 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
UA124619C2 (uk) 2015-09-21 2021-10-20 Вертекс Фармасьютікалз (Юроп) Лімітед Введення дейтерованих підсилювачів cftr

Similar Documents

Publication Publication Date Title
JP2018534348A5 (OSRAM)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2020097577A5 (OSRAM)
JP2016534063A5 (OSRAM)
JP2016534153A5 (OSRAM)
JP2024516371A5 (OSRAM)
JP2017518334A5 (OSRAM)
JP2015078230A5 (OSRAM)
JP2015510916A5 (OSRAM)
JP2014097964A5 (OSRAM)
JP2013032389A5 (OSRAM)
JP2012193216A5 (OSRAM)
JP2016517851A5 (OSRAM)
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
JP2016510326A5 (OSRAM)
JP2018504398A5 (OSRAM)
JP2013542261A5 (OSRAM)
JP2017533930A5 (OSRAM)
JP2016511753A5 (OSRAM)
JP2016515628A5 (OSRAM)
JP2017508817A5 (OSRAM)
JP2018530578A5 (OSRAM)
JP2016529306A5 (OSRAM)
JP2018521056A5 (OSRAM)
JP2016515550A5 (OSRAM)